SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
 - EconoTimes)
NEW ORLEANS, Aug. 11, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc. (NasdaqGS:FMI), if they purchased the Company’s shares between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Foundation Medicine, Inc. investors should visit us for more information about their rights at https://www.claimsfiler.com/cases/view-foundation-medicine-inc-securities-litigation\ or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Foundation Medicine and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the likelihood that the Company would be approved for reimbursement of its tumor tests by Medicare; (ii) the Company’s progress in doing so; (iii) the Company’s robust 2015 financial guidance; (iv) the assumption of Medicare approval on which its 2015 guidance was based; and (iv) as a result of the foregoing, Foundation’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
